Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised, double-blind, placebo-controlled phase 2 trial. (Q38774032)
Jump to navigation
Jump to search
scientific article published on 16 May 2017
Language | Label | Description | Also known as |
---|---|---|---|
English | Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised, double-blind, placebo-controlled phase 2 trial. |
scientific article published on 16 May 2017 |
Statements
Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised, double-blind, placebo-controlled phase 2 trial (English)
Michael A Matthay
J Stuart Elborn
Lj Mark Cross
Evie Gardner